アブストラクト | BACKGROUND: Establishing whether there is a potential relationship between glucagon-like peptide 1 receptor agonists (GLP-1RAs) and suicidal or self-injurious behaviors (SSIBs) is crucial for public safety. This study investigated the potential association between GLP-1RAs and SSIBs by exploring the FDA Adverse Event Reporting System (FAERS) database. METHODS: A disproportionality analysis was conducted using post-marketing data from the FAERS repository (2018 Q1 to 2022 Q4). SSIB cases associated with GLP-1RAs were identified and analyzed through disproportionality analysis using the information component. The parametric distribution with a goodness-of-fit test was employed to analyze the time-to-onset, and the Omega shrinkage was used to evaluate the potential effect of co-medication on the occurrence of SSIBs. RESULTS: In total, 204 cases of SSIBs associated with GLP-1RAs, including semaglutide, liraglutide, dulaglutide, exenatide, and albiglutide, were identified in the FAERS database. Time-of-onset analysis revealed no consistent mechanism for the latency of SSIBs in patients receiving GLP-1RAs. The disproportionality analysis did not indicate an association between GLP-1RAs and SSIBs. Co-medication analysis revealed 81 cases with antidepressants, antipsychotics, and benzodiazepines, which may be proxies of mental health comorbidities. CONCLUSIONS: We found no signal of disproportionate reporting of an association between GLP-1RA use and SSIBs. Clinicians need to maintain heightened vigilance on patients premedicated with neuropsychotropic drugs. This contributes to the greater acceptance of GLP-1RAs in patients with type 2 diabetes mellitus or obesity. |
ジャーナル名 | BMC medicine |
Pubmed追加日 | 2024/2/15 |
投稿者 | Zhou, Jianxing; Zheng, You; Xu, Baohua; Long, Songjun; Zhu, Li-E; Liu, Yunhui; Li, Chengliang; Zhang, Yifan; Liu, Maobai; Wu, Xuemei |
組織名 | Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, Fujian,;China.;School of Pharmacy, Fujian Medical University, Fuzhou, Fujian, China.;School of Medical Imaging, Fujian Medical University, Fuzhou, Fujian, China.;Department of Respiratory, Shanghai Electric Power Hospital, Shanghai, China.;Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai,;China. liumb0591@fjmu.edu.cn.;China. wuxuemei@fjmu.edu.cn.;wuxuemei@fjmu.edu.cn. |
Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/38355513/ |